• Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

  NCT04613557

  Active, not recruitingInterventionalPhase 1Updated Aug 31, 2023
• DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

  NCT03466320

  CompletedInterventionalPhase 1Phase 2Updated May 4, 2021
• A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

  NCT02848001

  TerminatedInterventionalPhase 1Updated Jun 12, 2025
• Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

  NCT00480987

  TerminatedInterventionalPhase 1Phase 2Updated Aug 7, 2012
• E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

  NCT01692197

  CompletedInterventionalPhase 2Updated Jul 3, 2018
• A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

  NCT05358379

  Unknown statusInterventionalPhase 1Phase 2Updated Feb 7, 2024

ClinicalTrials.gov ID

NCT04167696

Lead Sponsor

Celyad Oncology SAINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

27Estimated

Last Update Posted

Jun 9, 2020Actual

Start Date

Nov 25, 2019Actual

Primary Completion Date

Dec 2021Estimated

Completion Date

Feb 2035Estimated

Official Title

Open-label, Phase I, Multi-center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients the Recommended Dose of CYAD-02 After a Non-myeloablative Preconditioning Chemotherapy Followed by a Potential Consolidation Cycle

Brief Summary

An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patient. A maximum of 27 r/r AML/MDS patients will be evaluated in this study in case of no dose limiting toxicity (DLT) and no replacement of patients.

Detailed Description

This open-label phase I, multi-center study aims to determine in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patients.

During dose escalation, three prespecified dose-levels of CYAD-02 will be evaluated in three cohorts. Patient enrollment during dose-escalation will be staggered according to the Fibonacci 3+3 design and extension of cohorts II and III will be done in parallel. The first CYAD-02 infusion will be administered after prior non-myeloablative preconditioning chemotherapy (CYFLU) administered on three consecutive days.

Non-progressive patients meeting the criteria specified below may receive a consolidation cycle with three additional CYAD-02 infusions at a 2-week interval without prior preconditioning.

For all patients who received at least one CYAD-02 infusion, the overall study duration will be approximately 15 years.

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

• CYAD-02
• ENDOXAN
• Fludara

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria (main):

• The patient must not be eligible for standard of care therapy and have one of the following hematological malignancy:

  1. A confirmed relapsed or refractory acute AML (i.e. ≥ 5% blasts in bone marrow or in peripheral blood) with revised European LeukemiaNet (ELN) 2017 risk stratification for favorable, intermediate or adverse groups, after at least one prior therapy defined as either

     • Recurrence of disease after a first complete remission and not eligible for a second course of induction therapy, or
     • Recurrence of disease after a second complete remission, or
     • Failure to achieve a Complete Response after induction chemotherapy.

  2. A confirmed MDS as defined by revised International Prognostic Scoring System criteria for intermediate, high-risk or very high-risk disease or MDS with Tumor Protein 53 mutation as detected by next-generation sequencing, after failure of prior treatment with at least 4 cycles of azacitidine or decitabine defined as:

     • No response to treatment,
     • Loss of response at any time point, or
     • Intolerance to therapy.

• The patient must have evaluable disease as defined by:

  • Revised Recommendations of the International Working Group (IWG) for Diagnosis, Standardization of Response Criteria for AML patients,
  • IWG 2006 Uniform Response Criteria for patients with MDS.

• The absolute peripheral blast count should be < 15,000/L.

• The patient must have adequate hepatic and renal functions, as assessed by standard laboratory criteria.

• The patient must have a left ventricular ejection fraction of ≥ 40 %, as determined by echocardiography or a multigated acquisition scan.

• The patient must have a Forced Expiratory Volume (FEV) in the first second /Forced Vital Capacity = 0.7 with FEV-1 at 50 % predicted (GOLD 1 or 2 severity) as determined by spirometry

Exclusion Criteria (main):

• Patients with a confirmed or history of tumor involvement in the central nervous system
• Patients who have received any cancer therapy with therapeutic intent (investigational agent or not)
• Patients with any positive serology test results at baseline
• Patients who plan to receive, are concurrently receiving or have received any investigational agent within 3 weeks before the planned day for the first CYAD-02 infusion
• Patients with uncontrolled intercurrent illness or serious uncontrolled medical disorder
• Patients with significant coagulation disorder or who are receiving treatment with warfarin derivatives, heparin or direct oral anticoagulants
• Patients who have active infections
• Patients with documented history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis and/or active or acute exacerbation of chronic obstructive pulmonary disease

Primary Purpose

Treatment

Allocation

Non-Randomized

Interventional Model

Sequential Assignment

Masking

None (Open Label)

Lead Sponsor

Celyad Oncology SAINDUSTRY

yves.beguin@chuliege.be0032 4 242 52 00